Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

93 results

Filters applied: . Clear all
Page 1
Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial.
Espay AJ, Stocchi F, Pahwa R, Albanese A, Ellenbogen A, Ferreira JJ, Giladi N, Gurevich T, Hassin-Baer S, Hernandez-Vara J, Isaacson SH, Kieburtz K, LeWitt PA, Lopez-Manzanares L, Olanow CW, Poewe W, Sarva H, Yardeni T, Adar L, Salin L, Lopes N, Sasson N, Case R, Rascol O; BouNDless Study Group. Espay AJ, et al. Among authors: poewe w. Lancet Neurol. 2024 May;23(5):465-476. doi: 10.1016/S1474-4422(24)00052-8. Epub 2024 Mar 15. Lancet Neurol. 2024. PMID: 38499015 Clinical Trial.
The ongoing open-label extension phase will provide further information on the long-term efficacy and safety of treatment. FUNDING: NeuroDerm....
The ongoing open-label extension phase will provide further information on the long-term efficacy and safety of treatment. FUNDING: N …
Long-term safety and efficacy of open-label nabilone on sleep and pain in Parkinsons Disease.
Peball M, Heim B, Carbone F, Schorr O, Werkmann M, Ellmerer P, Marini K, Krismer F, Knaus HG, Poewe W, Djamshidian A, Seppi K. Peball M, et al. Among authors: poewe w. NPJ Parkinsons Dis. 2024 Mar 15;10(1):61. doi: 10.1038/s41531-024-00665-7. NPJ Parkinsons Dis. 2024. PMID: 38491070 Free PMC article.
This was a single-center open-label extension study to assess the long-term safety and efficacy of nabilone for NMS in PD. To be eligible for this study, patients had to be treatment responders during the previous NMS-Nab-trial and complete its double-blind phase without e …
This was a single-center open-label extension study to assess the long-term safety and efficacy of nabilone for NMS in PD. To be elig …
Cognitive dysfunction in de novo Parkinson disease: Remitting vs. progressive cognitive impairment.
Kawabata K, Djamshidian A, Bagarinao E, Weintraub D, Seppi K, Poewe W. Kawabata K, et al. Among authors: poewe w. Parkinsonism Relat Disord. 2024 Mar;120:105984. doi: 10.1016/j.parkreldis.2023.105984. Epub 2023 Dec 28. Parkinsonism Relat Disord. 2024. PMID: 38198926 Free article.
This study aimed to examine the clinical features of patients with different long-term cognitive trajectories in de novo PD over a five-year follow-up. ...These findings suggest individuals in RMD may still be at risk for cognitive deficits. However, further long-term …
This study aimed to examine the clinical features of patients with different long-term cognitive trajectories in de novo PD over a fi …
How Does Deep Brain Stimulation Change the Course of Parkinson's Disease?
Mahlknecht P, Foltynie T, Limousin P, Poewe W. Mahlknecht P, et al. Among authors: poewe w. Mov Disord. 2022 Aug;37(8):1581-1592. doi: 10.1002/mds.29052. Epub 2022 May 12. Mov Disord. 2022. PMID: 35560443 Free PMC article. Review.
In addition, subthalamic DBS is effective in controlling drug-refractory PD tremor. Here, we review the available data from long-term observational and controlled follow-up studies in DBS-treated patients to re-examine the persistence of motor and quality of life benefits …
In addition, subthalamic DBS is effective in controlling drug-refractory PD tremor. Here, we review the available data from long-term …
Associations of Gait Disorders and Recurrent Falls in Older People: A Prospective Population-Based Study.
Marini K, Mahlknecht P, Schorr O, Baumgartner M, De Marzi R, Raccagni C, Kiechl S, Rungger G, Stockner H, Willeit P, Willeit J, Poewe W, Seppi K. Marini K, et al. Among authors: poewe w. Gerontology. 2022;68(10):1139-1144. doi: 10.1159/000520959. Epub 2021 Dec 28. Gerontology. 2022. PMID: 34963115
Gait impairment has been linked to recurrent falls, but there are only limited long-term data on this association. OBJECTIVES: The objective of the study was to investigate the association of gait disorders (GDs) and gait tests with future falls in an existing longitudinal …
Gait impairment has been linked to recurrent falls, but there are only limited long-term data on this association. OBJECTIVES: The ob …
Subcutaneous Levodopa Infusion for Parkinson's Disease: 1-Year Data from the Open-Label BeyoND Study.
Poewe W, Stocchi F, Arkadir D, Ebersbach G, Ellenbogen AL, Giladi N, Isaacson SH, Kieburtz K, LeWitt P, Olanow CW, Simuni T, Thomas A, Zlotogorski A, Adar L, Case R, Oren S, Fuchs Orenbach S, Rosenfeld O, Sasson N, Yardeni T, Espay AJ; BeyoND study group. Poewe W, et al. Mov Disord. 2021 Nov;36(11):2687-2692. doi: 10.1002/mds.28758. Epub 2021 Sep 8. Mov Disord. 2021. PMID: 34496081 Free PMC article.
OBJECTIVE: Evaluate 1-year safety data. METHODS: BeyoND is an open-label study evaluating the long-term safety of two ND0612 dosing regimens. RESULTS: Of the 214 enrolled patients (24-hour SC infusion: n = 90; 16-hour SC infusion: n = 124), 120 (56%) completed 12 months of …
OBJECTIVE: Evaluate 1-year safety data. METHODS: BeyoND is an open-label study evaluating the long-term safety of two ND0612 dosing r …
Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study.
Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, Henriksen T, van Laar T, Lockhart D, Staines H, Lees A. Katzenschlager R, et al. Among authors: poewe w. Parkinsonism Relat Disord. 2021 Feb;83:79-85. doi: 10.1016/j.parkreldis.2020.12.024. Epub 2021 Jan 12. Parkinsonism Relat Disord. 2021. PMID: 33486139 Free article. Clinical Trial.
METHODS: All patients completing the 12-week DBP (including those switching early to open-label treatment) were offered OLP entry. The primary objective was the evaluation of long-term safety of APO. RESULTS: Eighty-four patients entered the OLP (40 previously on APO, 44 o …
METHODS: All patients completing the 12-week DBP (including those switching early to open-label treatment) were offered OLP entry. The prima …
Has Deep Brain Stimulation Changed the Very Long-Term Outcome of Parkinson's Disease? A Controlled Longitudinal Study.
Mahlknecht P, Peball M, Mair K, Werkmann M, Nocker M, Wolf E, Eisner W, Bajaj S, Quirbach S, Peralta C, Eschlböck S, Wenning GK, Willeit P, Seppi K, Poewe W. Mahlknecht P, et al. Among authors: poewe w. Mov Disord Clin Pract. 2020 Sep 21;7(7):782-787. doi: 10.1002/mdc3.13039. eCollection 2020 Oct. Mov Disord Clin Pract. 2020. PMID: 33033735 Free PMC article.
BACKGROUND: The long-term impact of deep brain stimulation (DBS) on Parkinson's disease (PD) is difficult to assess and has not yet been rigorously evaluated in comparison to its natural history. ...
BACKGROUND: The long-term impact of deep brain stimulation (DBS) on Parkinson's disease (PD) is difficult to assess and has not yet b …
The Frontal Assessment Battery in RLS patients with and without augmentation.
Ellmerer P, Stefani A, Heim B, Bergmann M, Seppi K, Poewe W, Högl B, Djamshidian A. Ellmerer P, et al. Among authors: poewe w. Sleep Med. 2020 Nov;75:456-458. doi: 10.1016/j.sleep.2020.09.010. Epub 2020 Sep 10. Sleep Med. 2020. PMID: 32998091
CONCLUSIONS: Our findings suggest an impaired executive function in RLS/WED patients with augmentation compared to RLS/WED patients without augmentation and healthy controls. Long term neuroplastic changes within the prefrontal cortex may be the underlying cause for these …
CONCLUSIONS: Our findings suggest an impaired executive function in RLS/WED patients with augmentation compared to RLS/WED patients without …
Deep brain stimulation reduces (nocturnal) dyskinetic exacerbations in patients with ADCY5 mutation: a case series.
de Almeida Marcelino AL, Mainka T, Krause P, Poewe W, Ganos C, Kühn AA. de Almeida Marcelino AL, et al. Among authors: poewe w. J Neurol. 2020 Dec;267(12):3624-3631. doi: 10.1007/s00415-020-09871-8. Epub 2020 Jul 9. J Neurol. 2020. PMID: 32647899 Free PMC article.
Episodic exacerbations of dyskinesia are a particularly disturbing symptom as they occur predominantly during night and interrupt sleep. We present the clinical short- and long-term effects of pallidal deep brain stimulation (DBS) in three patients with a confirmed pathoge …
Episodic exacerbations of dyskinesia are a particularly disturbing symptom as they occur predominantly during night and interrupt sleep. We …
93 results